Can Spatial Immune Profiling Improve Oncotype Dx Guidance of Chemotherapy in Breast Cancer?

Predictions of late recurrence risk in ER+HER2- breast cancer patients remain suboptimal, particularly for patients with intermediate risk determined by the Oncotype Dx Recurrence Score (RS, 16-25). Using spatial proteomics (multiplex immunofluorescence) and spatial transcriptomics, our guest, Zak Kinsella PhD, from the Royal College of Surgeons in Ireland, with his team of co-authors, observed an association between higher stromal tumor-infiltrating CD8+ lymphocyte (sTIL CD8+) density and poor outcome (ΔLR-χ2: 6.79, p = 0.009). The study suggests sTIL CD8+ density as a candidate biomarker for treatment decisions. Nature Communications ( 2026);

Learn more about Nature Communications

#OncotypeDX

#BreastCancer

#ERPositive

#HER2Negative

#CD8TCells

#SpatialOmics

#TumorMicroenvironment